Is Methotrexate Therapy for Psoriasis Carcinogenic?: A Modified Retrospective-Prospective Analysis

JAMA: The Journal of the American Medical Association

Volumn 232, Issue 4, 1975, Pages 359-362

  Bailin, Philip L ^a   Tindall, John P ^b   Roenigk, Henry H ^a   Hogan, Michael D ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADVERSE DRUG REACTION; CANCER MORTALITY; CANCER STATISTICS; CARCINOGENESIS; CHEMOTHERAPY; DRUG THERAPY; DRUG TOXICITY; LIVER DISEASE; LIVER TOXICITY; PSORIASIS; STATISTICS; THERAPY;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; LIVER; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGE; NEOPLASMS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PSORIASIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 0016688052     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1975.03250040013017     Document Type: Article

References (22)

1. 1. Roenigk HH Jr, Fowler-Bergfeld W, Curtis GH: Methotrexate for psoriasis in weekly oral doses. Arch Dermatol 99:86-93, 1969.
2. 2. Rees RB, Bennett JH, Maibach HI, et al: Methotrexate for psoriasis. Arch Dermatol 95:2-11, 1967.
3. 3. Dahl MG, Gregory MM, Scheuer PJ: Methotrexate hepatotoxicity in psoriasis: Comparison of different dose regimens. Br Med J 1:654-656, 1972
4. 4. Weinstein G, Roenigk HH Jr, Maibach HI, et al: Psoriasis-liver-methotrexate interactions. Arch Dermatol 108:36-42, 1973.
5. 5. Epstein WL, Maibach HI: Immunologic competence of patients with psoriasis receiving cytotoxic drug therapy. Arch Dermatol 91:599-606, 1965.
6. 6. Penn I: Malignant Tumors in Organ Transplant Recipients. New York, Springer-Verlag, 1970.
7. 7. Gatti RA, Good RA: Occurrence of malignancy in immunodeficiency diseases: A literature review. Cancer 28:89-98, 1971.
8. 8. Waldman TA, Strober W, Blase RM: Immunodeficiency diseases and malignancy: Various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. Ann Intern Med 77:605-628, 1972.
9. 9. Burnet FM: Cancer: A biological approach. Br Med J 1:779-786, 841-847, 1957.
10. 10. Burnet FM: Immunologic surveillance in neoplasia. Transplant Rev 7:3-25, 1971.
11. 11. Schwartz RS: Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet 1:1266-1269, 1972.
12. 12. Stevens DA: Immunosuppression and virus infections. Transplant Proc 5:1259-1262, 1973.
13. 13. Lecatsas G, Prozesky OW, Van Wyk J, et al: Papova virus in urine after renal transplantation. Nature 241:343-344, 1973.
14. 14. Penn I, Starzl TE: Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation 14:407-417, 1972.
15. 15. Hoover R, Fraumeni JF: Risk of cancer in renal-transplant recipients. Lancet 2:55-57, 1973.
16. 16. Harris CC: Malignancy during methotrexate and steroid therapy for psoriasis. Arch Dermatol 103:501-504, 1971.
17. 17. Craig SR, Rosenberg EW: Methotrexate-induced carcinoma? Arch Dermatol 103:505-506, 1971.
18. 18. Molin L, Larsen TE: Psoriasis, methotrexate, and cancer. Arch Dermatol 105:292, 1972.
19. 19. Penn T, Starzl TE: The Effect of Immunosuppression on Cancer: Seventh National Cancer Conference Proceedings. Philadelphia, JB Lippincott Co, 1973, pp 425-436.
20. 20. Shklar G, Cataldo E, Fitzgerald AL: The effect of methotrexate on chemical carcinogenesis of hamster buccal pouch. Cancer Res 26:2218-2220, 1966.
21. 21. Vital Statistics of the United States, 1967, vol 2, pt B. US Department of Health, Education, and Welfare, Public Health Service, US Government Printing Office.
22. 22. Third National Cancer Survey, 1969 Incidence, preliminary report. Biometry Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.